ASH 2020: Monthly Subcutaneous Fitusiran Reduces Bleeding in Hemophilia A and B
Investigational fitusiran is effective regardless of factor deficiency subtype
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.